All articles tagged with #cancer research
Many cancers can recur years after initial treatment due to dormant tumour cells that evade therapy and immune detection, with ongoing research aiming to understand and target these cells to prevent relapse.
Florida Panthers GM Bill Zito is auctioning life-sized panther sculptures, painted by artists and celebrities, to raise funds for cancer research, with the campaign having already raised $700,000 and ongoing bidding through Charitybuzz until February 6.
Scientists have discovered that in colorectal cancer, two subtypes of regulatory T cells play opposing roles, with one subtype helping to restrain tumor growth and the other promoting it. This finding could lead to more targeted immunotherapies that selectively eliminate harmful Tregs, improving outcomes for patients.
New blood tests like the Grail Galleri offer hope for early detection of pancreatic cancer, which is crucial as most cases are diagnosed late with poor survival rates. Early detection can significantly improve treatment outcomes, but current screening options are limited, and the disease remains deadly, especially in Ohio where incidence and mortality rates are high. Researchers emphasize the importance of clinical trials and awareness efforts to improve prognosis and develop better therapies.
Researchers at UBC Okanagan have decoded how plants produce mitraphylline, a rare compound with potential anti-cancer properties, by identifying key enzymes involved in its biosynthesis, paving the way for sustainable drug production.
Scientists have created a detailed 4D map of the human genome, revealing how its components interact over time in three dimensions, which could lead to advances in understanding gene regulation and developing new cancer therapies.
Fernando Goldsztein, whose son Frederico was diagnosed with medulloblastoma, has dedicated his life to finding a cure for this rare childhood brain tumor by founding the Medulloblastoma Initiative, which has raised $13 million and is working on new clinical trials to improve treatment options for affected children worldwide.
Fernando Goldsztein, whose son Frederico was diagnosed with medulloblastoma, a rare and aggressive childhood brain tumor, has dedicated his life to finding a cure by founding the Medulloblastoma Initiative, which has raised $13 million and is conducting clinical trials to develop new treatments, aiming to save not only his son but thousands of other children affected by this disease.
University of Michigan researchers have made a significant breakthrough in treating acute myeloid leukemia by advancing understanding of protein interactions that drive the disease, leading to improved care options for patients.
Researchers at the University of Navarra have developed RNACOREX, an open-source software that maps gene regulation networks in cancer, helping to understand tumor behavior and predict patient survival with clear, interpretable results, advancing personalized cancer treatment.
The study investigates how loss of driver mutations like Apc and Ctnnb1 shapes intestinal tumor development, revealing that priming with mutations such as KRAS influences the mutation landscape, mutation patterns, and tumor evolution, with implications for understanding colorectal cancer progression.
The study reveals that TGF-β creates a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1+ macrophages, contributing to immune evasion and tumor progression.
The study reveals that the lymph node microenvironment promotes resistance to ferroptosis in metastasizing melanoma by downregulating GSH synthesis and upregulating FSP1, which localizes to lysosomes and provides a GPX4-independent protective mechanism. Oxygen levels and epigenetic regulation influence GPX4 stability and ferroptosis sensitivity, suggesting potential therapeutic strategies targeting FSP1 and GSH synthesis in LN metastases.
Genome-scale CRISPR screens identified PTGES3 as a key regulator of androgen receptor (AR) stability and activity in advanced prostate cancer, revealing its potential as a therapeutic target to overcome resistance to AR-targeted therapies in castration-resistant prostate cancer (CRPC).
This study explores how epigenetic changes and immune microenvironment interactions drive early immune evasion in colorectal cancer, highlighting chromatin architecture's role in suppressing neoantigen expression and the importance of early immune escape mechanisms in tumor evolution.